Recommendations to facilitate expanded access to investigational therapies for seriously ill patients

Academic Medicine

Volumn 91, Issue 3, 2016, Pages 305-309

  Jerome, Rebecca N ^a   Edwards, Terri L ^a   Boswell, Haley C ^a   Bernard, Gordon R ^a   Harris, Paul A ^b   Pulley, Jill M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COMPASSIONATE USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HUMAN; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; UNITED STATES;

COMPASSIONATE USE TRIALS; DRUGS, INVESTIGATIONAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84958899259     PISSN: 10402446     EISSN: 1938808X     Source Type: Journal    
DOI: 10.1097/ACM.0000000000000914     Document Type: Review

References (34)

1. U.S. Food and Drug Administration. Expanded access: Information for patients. http://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm20041768.htm. Accessed July 9, 2015.
2. Code of Federal Regulations, Title 21. U.S. Food and Drug Administration. Expanded access to investigational drugs for treatment use. Final rule. 21 C.F.R. §§312, 316 (2009).
3. Code of Federal Regulations, Title 21. U.S. Food and Drug Administration. Charging for investigational drugs under an investigational new drug application. Final rule. 21 C.F.R. §312 (2009).
4. U.S. Food and Drug Administration. Guidance for industry: Expanded access to investigational drugs for treatment use-Qs & As. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf. Accessed July 10, 2015.
5. U.S. Food and Drug Administration. Expanded access INDs and protocols: Expanded access submission receipts reports, 2010-2014. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/INDActivityReports/ucm373560.htm. Accessed July 10, 2015.
6. Brower V. Food and Drug Administration responds to pressure for expanded drug access. J Natl Cancer Inst. 2014;106:dju171.
7. Mack GS. Expanded access rules pose quandary for drug developers. Nat Biotechnol. 2009;27:871-872.
8. Jacobson PD, Parmet WE. A new era of unapproved drugs: The case of Abigail Alliance v Von Eschenbach. JAMA. 2007;297:205-208.
9. Freedman RS, Markman M. Food and Drug Administration expanded access to treatment: Implications for oncology patients. Cancer. 2007;109:2157-2160.
10. Cohen E. Dying patients denied drugs. CNN. April 6, 2014. http://edition. cnn.com/2014/04/05/health/cohencompassionate-use/. Accessed July 10, 2015.
11. Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384:1896-1899.
12. Biotechnology Industry Organization (BIO). BIO statement on compassionate use. March 18, 2014. https://www.bio.org/articles/biostatement-compassionate-use. Accessed July 10, 2015.
13. Pharmaceutical Research and Manufacturers of America. Biopharmaceutical companies reaffirm commitment to patients in updated principles of conduct of clinical trials and communication of clinical trial results. December 10, 2014. http://www.phrma.org/catalyst/expanded-access-to-investigationaldrugs. Accessed July 10, 2015.
14. Sanghavi D, George M, Bencic S. Health policy issue brief: Four A's of expanding access to life-saving treatments and regulatory implications. Brookings Institute Web site. July 31, 2014. http://www. brookings.edu/research/papers/2014/07/29-compassionate-use-of-pharmaceuticaldrugs. Accessed July 10, 2015.
15. Goldwater Institute. Everyone deserves the right to try: Empowering the terminally ill to take control of their treatment. February 11, 2014. http://goldwaterinstitute.org/en/work/topics/healthcare/right-to-try/everyonedeserves-right-try-empowering-terminally-/. Accessed July 10, 2015.
16. Zettler PJ, Greely HT. The strange allure of state "right-to-try" laws. JAMA Intern Med. 2014;174:1885-1886.
17. Winniford A. Expanding access to investigational drugs for treatment use: A policy analysis and legislative proposal. Health Matrix Clevel. 2009;19:205-246.
18. 21st Century Cures Act, H.R. 6, 114th Cong (2015). https://www.congress.gov/bill/114thcongress/house-bill/6. Accessed July 16, 2015.
19. Right to Try Act of 2015, H.R. 3012, 114th Cong (2015). https://www.congress.gov/bill/114th-congress/house-bill/3012. Accessed July 16, 2015.
20. Abigail Alliance for Better Access to Developmental Drugs v Von Eschenbach, 495 F3d 695 (DC Cir 2007)(en banc), cert. denied, 128 S Ct 1069 (2008).
21. Scichilone N, Basile M, Battaglia S, Bellia V. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration. 2014;87:11-17.
22. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol. 2001;19:1728-1733.
23. Clarey J, Kao SC, Clarke SJ, Vardy J. The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Ann Oncol. 2012;23:1229-1233.
24. U.S. Food and Drug Administration. Prescription Drug User Fee Act patientfocused drug development: Request for comments. Fed Reg. 2014;29:60857-60859.
25. Wilgenhof S, Du Four S, Everaert H, Neyns B. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: Five illustrative case reports. Cancer Invest. 2012;30:712-720.
26. Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1? inhibitor gevokizumab. Br J Dermatol. 2015;173:239-241.
27. Rockoff JD. J&J changes 'compassionate' care-independent panel to review requests from seriously ill patients for unapproved medicine. Wall Str J (East ed). May 7, 2015:B1.
28. Bernard GR. Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci. 2012;5:121-129.
29. Flynn KE, Hahn CL, Kramer JM, et al. Using central IRBs for multicenter clinical trials in the United States. PLoS One. 2013;8:e54999.
30. IRBshare. http://irbshare.org/. Accessed July 10, 2015.
31. Internal Revenue Service. Corporations (publication 542). Revised March 2012. http://www.irs.gov/publications/p542/index. html. Accessed July 10, 2015.
32. U.S. Food and Drug Administration. Guidance for industry: Individual patient expanded access applications: Form FDA 3926. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM432717.pdf. Accessed July 16, 2015.
33. Yao L. FDA takes step to encourage pediatric drug studies. August 26, 2013. http://blogs. fda.gov/fdavoice/index.php/2013/08/fdatakes-step-to-encourage-pediatric-drugstudies/. Accessed July 10, 2015.
34. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: One participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997;126:892-897.